Clinical trial
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
NCT00047502 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00047502 |
|---|---|
| Title | Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia |
| Official title | Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Lonafarnib (SCH66336), Imatinib Mesylate (Gleevec) |
| Enrollment | 23 |
| Start date | Nov 1, 2002 |
| Primary completion | Apr 10, 2006 |
| Completion | Apr 10, 2006 |
| First posted | Oct 9, 2002 |
| Last update posted | Nov 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: